Gencurix Amends Payment Schedule for Subsidiary Nanobiolife Stake Sale
Gencurix has amended its material disclosure regarding the sale of its subsidiary Nanobiolife shares, originally filed on December 24, 2024.
The amendment revises the cash payment schedule, postponing a 500 million won payment from December 31, 2025 to December 24, 2026.
The total transaction value of 5,639,418,720 won remains unchanged, and an external valuation confirmed the fairness of the price.
This correction represents a minor change in payment timing with negligible impact on total assets.
[AI Summary]This amendment adjusts the payment schedule for the subsidiary stake sale without altering the total consideration or core terms. The impact on shareholder value is minimal, and the original purpose of improving financial structure remains intact.
KOSDAQ Filing Information
[Correction of Description] Report on Major Matters (Decision on Transfer of Stocks and Investment Securities of Other Corporations)